Over a decade in the past, a bunch of researchers led by two diabetes experts, Richard DiMarchi and Matthias Tschöp, published a landmark paper in mice that suggested a brand new solution to deal with obesity and diabetes.
The drug within the examine activated two intestine hormone receptors — the now famous GLP-1 and its much less appreciated sibling GIP. Eli Lilly went on to make use of that approach to develop tirzepatide, the diabetes and weight reduction medicine Mounjaro and Zepcertain.
Unlock this text immediately by turning into a free subscriber.
You’ll get entry to free articles every month, plus you may customise what newsletters get delivered to your inbox every week, together with breaking information.